Home > Pulmonology > ERS 2022 > Encouraging results of nintedanib in children with fibrosing ILD

Encouraging results of nintedanib in children with fibrosing ILD

Presented By
Dr Robin Deterding, Children’s Hospital Colorado, CO, USA
Conference
ERS 2022
Trial
Phase 3, InPedILD
With an acceptable safety profile and promising efficacy data, nintedanib is a potential candidate for treating children and adolescents with fibrosing interstitial lung disease (ILD). There is a clear medical need to find treatment options for childhood ILD. Similarities are found in the pathophysiology of fibrotic lung remodelling in adults and children and the demonstrated benefit of nintedanib in adults with fibrosing ILD [1,2]. To this end, Dr Robin Deterding (Children’s Hospital Colorado, CO, USA) and colleagues designed the phase 3 InPedILD trial (NCT04093024) [3,4]. Patients aged 6-17 with fibrosing ILD (n=39) were randomised 2:1 to nintedanib or placebo in the 24-week, double-blind period. Hereafter, all participants received nintedanib in the open-label phase of the trial. Nintedanib dose was based on weight, ranging from 50 mg, twice daily...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on